Remove

Under the Paperwork Reduction Act of 1995, no persons are required to respo

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10595787		
Filing Date		2006-05-11		
First Named Inventor BUR		GSTALER et al.		
Art Unit		N/A		
Examiner Name	N/A			
Attorney Docket Numb	er	72216		

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant		Releva	Columns,Lines where ant Passages or Relev s Appear	
	1	6354171		2002-03-12	Wolpert et al.				
	2	3937994		1976-02-10	Presiey et al.		3, 4		
	3	6193022		2001-02-27	Bode		5, 6		
If you wisi	h to a	dd additional U.S. Pater	t citatio	n information	please click the	Add button.		Add	
			U.S.P	ATENT APP	ICATION PUB	LICATIONS		Remove	
Examiner Initial*	xaminer Cite Publication Number Kind Publication Name of Patentee of Applicant Relev				Releva	Columns,Lines where ant Passages or Relev Appear			
	1	20020027386		2002-03-07	Yanaka et al.		1-4, 7-	15, 5, 6	
	2	20030033073		2003-02-13	Kıchima et al.		1		
If you wish	h to a	dd additional U.S. Publi:	shed Ap	plication citat	on information	please click the Ad	d button	Add	_
				FOREIGN P	ATENT DOCUM	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication e ⁴ Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS

U.S.PATENTS

| INFORMATION DISCLOSURE | Application Number | 10595787 | Filing Date | 2006-05-11 | Filing Date | 20

	1	EP1059208A2	EP	2000-12-13	Mueller et al.		$ \Box $
	2	EP1004491A2	EP	2000-05-31	Aızawa	1-4	
	3	DE19926604C1	DE	2000-11-23	Wolpert et al.	1-4, 7-15	
	4	WO03/008248A1	AU	2003-01-30	Wang	5, 6	
	5	DE10061006A1	DE	2002-06-13	Ewinger et al.	7-11	
	6	EP1085240A1	EP	2001-03-21	Tamasho et al.	12-15	
	7	DE3909907A1	DE	1990-09-27	Ahner et al.	1, 5, 6	
	8	DE19653961A1	DE	1998-06-25	Genter et al.	5, 6	
	9	DE10064770C2	DE	2002-09-05	Burgstaler et al.		
If you wis	h to a	dd additional Foreign P			ease click the Add button		
				 ERATURE DO		Remove	
Examiner	Cite				the article (when appropriate pages(s) volume is		т5

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

publisher, city and/or country where published.

T5

Initials* No.

	Application Number		10595787	
	Filing Date		2006-05-11	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor BUR		GSTALER et al.	
(Not for submission under 37 CFR 1.99)	Art Unit		N/A	
(Not for Submission under or or trissy	Examiner Name N/A			
	Attorney Docket Numb	er	72216	

 	_
	_
1	l ⊔

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Patent Documents at inverUSPTO_GOLY or MPEP 901.94. 2 Enter office that issued the document, by the involved own (WIPO Standard ST3.). **Produces persist or counters, the oricidation of the year of the region of the Emperor many precede the settle involved the patent document.
**Aircl of document by the appropriate symbols as endicated on the document under WIPO Standard ST3.16 if possible, **Applicant is to place a check mark here it
"English languages bresistation is distracted."

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10595787		
Filing Date		2006-05-11		
First Named Inventor	BURG	GSTALER et al.		
Art Unit		N/A		
Examiner Name	N/A			
Attorney Docket Number		72216		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
7	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(eV1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

_	See attached	cortification	etatement

	Fee set forth in 37	CFR 1.17	(p) has been submitted herewith.
--	---------------------	----------	----------------------------------

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/john james mcglew/	Date (YYYY-MM-DD)	2006-05-12
Name/Print	John James McGlew	Registration Number	31903

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient of the principal principal

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as and of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4U S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of the
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.